Subbulaxmi Trikudanathan, MD
Endocrinology, Diabetes & Metabolism · Seattle, WANPI 1174782494
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,825 of the $2,014 with a category attached, or 90.6%. Regeneron accounts for 90.6% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $1,825 and has fallen 98.2% since, to $32 in 2024.
Across 4 payments — averaging $503.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$2K
- Boehringer Ingelheim$125
- Novo Nordisk$65
Across 18 payments — averaging $3237.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$38K
- Novo Nordisk AS$18K
- Lexicon Pharmaceuticals, Inc.$2K
What the payments were for
- Consulting fees$1,82591%
- Food & beverage$1256%
- Education$653%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 1 | $1,825 |
| Boehringer Ingelheim | 1 | $125 |
| Novo Nordisk | 2 | $65 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$1,825
How this compares
$2,014 in reported general payments places this provider in the 65th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
See all endocrinology, diabetes & metabolism providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 83 | $122,713 |
| JardianceEmpagliflozin | 49 | $79,685 |
| MounjaroTirzepatide | 44 | $54,942 |
| TrulicityDulaglutide | 33 | $34,474 |
| TradjentaLinagliptin | 11 | $16,937 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $14,603 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $9,145 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $6,389 |
| Novolog FlexpenInsulin Aspart | 15 | $4,483 |
| Humalog Kwikpen U-100Insulin Lispro | 17 | $3,075 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 15 | $2,918 |
| Ultra-Fine Nano Pen NeedlePen Needle, Diabetic | 18 | $2,740 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 19 | $2,216 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 14 | $1,685 |
| Metformin Hcl ErMetformin Hcl | 59 | $1,088 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $65 | $122,71383 claims |
| Boehringer IngelheimJardiance, Tradjenta | $125 | $96,62260 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
Other endocrinology, diabetes & metabolism in Seattle
- Irl HirschSeattle$192K
- Nicole EhrhardtSeattle$111K
- Kristina UtzschneiderSeattle$72K
- Savitha SubramanianSeattle$71K
- William HagopianSeattle$30K
- Mahnaz MellatiSeattle$28K
- Alan ChaitSeattle$21K
- Jose GarciaSeattle$12K
- Carla GreenbaumSeattle$7K
- Tracy TyleeSeattle$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.